Integrated in silico investigation of an androstendiol derivative (monoxetanol) as a potential anti-prostate cancer agent: insights from molecular docking, MD simulations, MM/PBSA, ADMET, and DFT analyses. - Bekkar Y; Elhafnaoui L; Al-Masoudi NA; Abdul-Rida NA; Al-Masoudi WA; Mahdi AM (In silico pharmacology, 2026)